

Wholesale Value Fund

MONTHLY UPDATE • FEBRUARY 2014

FUND FACTS

FUND COMMENCED	2 Sep 2004
MIN. INVESTMENT	\$10,000
INCOME DISTRIBUTION	Quarterly
APPLICATIONS/ REDEMPTION	Weekly

UNIT PRICE SUMMARY

DATE	28 Feb 2014
BUY PRICE	\$1.5043
REDEMPTION PRICE	\$1.4967
MID PRICE	\$1.5005
PORTFOLIO VALUE	\$32.5m

RESPONSIBLE ENTITY

Macro Capital Ltd
P +61 8 9217 3100
F +61 8 9217 3111
info@macrofunds.com.au

INVESTMENT MANAGER

Intelligent Investor Funds Pty Ltd
+61 2 8305 6050
admin@iifunds.com.au
www.iifunds.com.au

DISCLAIMER This report was prepared by Intelligent Investor Funds Pty Limited, Authorised Representative 350801 of Intelligent Investor Publishing Pty Limited AFSL No: 282288. Macro Capital Limited (AFSL No 392401) as the Responsible Entity is the issuer of the Intelligent Investor Wholesale Value Fund (ARSN No: 110 619 488). You should obtain and consider a copy of the product disclosure statement relating to the Intelligent Investor Wholesale Value Fund before acquiring the financial product. You may obtain a product disclosure statement from Macro Capital Limited or download a copy at www.macrofunds.com.au. To the extent permitted by law, Macro Capital Limited and Intelligent Investor Funds Pty Limited, its employees, consultants, advisers, officers and authorised representatives are not liable for any loss or damage arising as a result of reliance placed on the contents of this report.

February was a modest month for the Intelligent Investor Wholesale Value Fund with the unit price decreasing 0.1%. Over the same period the benchmark All Ordinaries Accumulation Index rose a roaring 4.8%, reversing its losses of 2.8% in January and then some.

Many of the companies the Fund owns reported results during February and the news was mostly pleasing.

SUMMARY OF RETURNS AS AT 28 FEB 2014

	WHOLESALE FUND (%)	S&P ALL ORDS. ACCUM. INDEX (%)
1 MONTH RETURN	-0.13	4.84
3 MONTH RETURN	0.98	2.88
6 MONTH RETURN	7.69	7.95
1 YEAR RETURN	26.84	10.37
2 YEAR RETURN (PA)	26.75	15.98
3 YEAR RETURN (PA)	21.78	7.88
SINCE INCEPTION* (PA)	7.83	8.95

* 2 Sep 2004

RNY Property Trust, the Fund's biggest investment, owns office property in the New York tri-state area. Occupancy at RNY's offices fell marginally to 81% in 2013, which was a creditable result due to significant lease expirations in the period. Net asset value increased 6% over the past six months to \$0.54 per unit but this was due to debt forgiveness and currency movements. Property values fell 1.5% in US dollars.

The underlying drivers still look good for future asset valuation increases, and RNY's unit price rose 7.8% in February to finish at \$0.35. That's still an attractive 35% discount to today's net asset value, which may be conservative if US employment markets continue to improve. Management indicated they will work on retaining tenants and improving occupancy before investigating opportunities to return money to RNY investors.

TOP 5 HOLDINGS

STOCK	PORTFOLIO WEIGHTING (%)
RNY PROPERTY TRUST	15.30
GBST	8.07
VISION EYE INSTITUTE	8.04
ENERGO GROUP	6.38
SERVICE STREAM	6.25

Vision Eye Institute, which provides eye-health services to patients through specialist doctors known as ophthalmologists, reported net profit after tax of \$7.5m for the half year, an increase of 53%. The increase in profit however was driven by lower debt, and the one off proceeds from an insurance claim. Underlying operating earnings fell 6%.


For the bulls, the business showed its resilience in the face of government-mandated reductions in its day surgery rates and continued to throw off plenty of free cash flow. But there was also plenty of fodder to feed the bears' concerns. The percentage of revenue paid to its doctors rose further and the commentary suggested there is no letup in sight. Ophthalmologists tightly control the supply of new entrants and those that make it through have all of the bargaining power with a business like Vision.

Vision's share price fell 13% to \$0.58 during the month and, whilst we think it looks cheap at those levels, this fundamental weakness justifies Vision trading at a substantially lower multiple than other healthcare stocks with stronger market positions.

The latest result from **Enero Group** suggests the troubled marketing services provider has finally stopped the rot. Turnover fell 6.5% compared to the prior period but operating margins, excluding depreciation, amortisation, impairments and restructure expenses, improved to 8.1%.

Though this is still around half the margins Enero's peers produce the share price had been factoring in worse. Enero shares rallied 30% through the month and now trade at \$0.90.

COMPARISON OF \$10,000 INVESTED IN THE WHOLESALE VALUE FUND VS ASX ALL ORDS INDEX SINCE INCEPTION (2 SEP 2004)



Source: Capital IQ, Feb 2014; Intelligent Investor Funds

Financial software provider **GBST** reported an 18% increase in half year revenue, and an 8% increase in earnings before interest, tax, depreciation and amortisation to \$9.4m. The results were flattered by the stronger UK pound, which was 12% higher, but the revenue growth was nonetheless impressive.

GBST's rapidly growing wealth management division dragged margins down thanks to higher research and development costs, including a new offshore development centre in Vietnam. Competition is increasing in the UK wealth management market – rival Bravura has apparently stepped up its efforts – but GBST remains exceptionally well placed in this growing market. The share price increased 17% during February and 183% in the past 12 months.